

# Pierre-Antoine Bonnet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1715023/publications.pdf>

Version: 2024-02-01

50  
papers

1,260  
citations

361045

20  
h-index

360668

35  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1504  
citing authors

#	ARTICLE	IF	CITATIONS
1	HMOX1 and NQO1 Genes are Upregulated in Response to Contact Sensitizers in Dendritic Cells and THP-1 Cell Line: Role of the Keap1/Nrf2 Pathway. <i>Toxicological Sciences</i> , 2009, 107, 451-460.	1.4	126
2	Identification and quantification of 14 phthalates and 5 non-phthalate plasticizers in PVC medical devices by GC-MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 949-950, 99-108.	1.2	125
3	In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 6601-6610.	1.4	104
4	The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizers. <i>Toxicology and Applied Pharmacology</i> , 2006, 212, 14-23.	1.3	90
5	Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. <i>European Journal of Medicinal Chemistry</i> , 2020, 193, 112238.	2.6	77
6	Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 850, 376-383.	1.2	54
7	Analytical method for the identification and assay of 12 phthalates in cosmetic products: Application of the ISO 12787 international standard "Cosmetics" Analytical methods "Validation criteria for analytical results using chromatographic techniques". <i>Journal of Chromatography A</i> , 2012, 1253, 144-153.	1.8	47
8	New imidazo[1,2-a]quinoxaline derivatives: Synthesis and in vitro activity against human melanoma. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3406-3411.	2.6	45
9	EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-1-associated adult T-cell leukemia/lymphoma. <i>Blood</i> , 2008, 111, 3770-3777.	0.6	36
10	Raman chemical imaging for spectroscopic screening and direct quantification of falsified drugs. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 316-323.	1.4	35
11	New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structure-activity relationships. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2433-2440.	1.4	32
12	Relaxivity enhancement of low molecular weight nitroxide stable free radicals: Importance of structure and medium. <i>Magnetic Resonance in Medicine</i> , 1994, 32, 11-15.	1.9	31
13	Novel and Selective TLR7 Antagonists among the Imidazo[1,2-a]pyrazines, Imidazo[1,5-a]quinoxalines, and Pyrazolo[1,5-a]quinoxalines Series. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7015-7031.	2.9	31
14	Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 1129-1139.	1.4	30
15	Isolation and structure elucidation of a highly haemolytic saponin from the Merck saponin extract using high-field gradient-enhanced NMR techniques. <i>Carbohydrate Research</i> , 1997, 302, 67-78.	1.1	29
16	Imidazo[1,2-a]quinoxalines: synthesis and cyclic nucleotide phosphodiesterase inhibitory activity. <i>European Journal of Medicinal Chemistry</i> , 2001, 36, 255-264.	2.6	26
17	New imidazo[1,2-a]pyrazine derivatives with bronchodilatory and cyclic nucleotide phosphodiesterase inhibitory activities. <i>Bioorganic and Medicinal Chemistry</i> , 1999, 7, 1059-1065.	1.4	24
18	Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 23-29.	1.9	24

#	ARTICLE	IF	CITATIONS
19	EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by <i>Leishmania major</i> and <i>Leishmania tropica</i> . <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006854.	1.3	24
20	Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 909-919.	2.6	22
21	Tungsten determination in rat and dog plasma samples by inductively coupled plasma emission spectrometry. <i>Analytica Chimica Acta</i> , 2000, 405, 221-226.	2.6	20
22	Qualitative and quantitative evaluation of a local lymph node assay based on ex vivo interleukin-2 production. <i>Toxicology</i> , 2005, 206, 285-298.	2.0	18
23	New IKK inhibitors: Synthesis of new imidazo[1,2-a]quinoxaline derivatives using microwave assistance and biological evaluation as IKK inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 115, 268-274.	2.6	16
24	An in-line enzymatic microreactor for the middle-up analysis of monoclonal antibodies by capillary electrophoresis. <i>Analyst</i> , 2020, 145, 1759-1767.	1.7	16
25	EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells. <i>Anti-Cancer Drugs</i> , 2014, 25, 624-632.	0.7	15
26	Carboxylic acid or primary amine titration at the lipid-water interface: on the role of electric charges and phospholipid acyl chain composition. A spin labeling experiment. <i>Chemistry and Physics of Lipids</i> , 1990, 55, 133-143.	1.5	14
27	Metabolism and Pharmacokinetics of EAPB0203 and EAPB0503, Two Imidazoquinoxaline Compounds Previously Shown to Have Antitumoral Activity on Melanoma and T-Lymphomas. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1836-1847.	1.7	14
28	Characterization of a New Anticancer Agent, EAPB0203, and Its Main Metabolites: Nuclear Magnetic Resonance and Liquid Chromatography-Mass Spectrometry Studies. <i>Analytical Chemistry</i> , 2012, 84, 9865-9872.	3.2	12
29	Imidazo[1,2-a]quinoxalines Derivatives Grafted with Amino Acids: Synthesis and Evaluation on A375 Melanoma Cells. <i>Molecules</i> , 2018, 23, 2987.	1.7	12
30	Imiquimod Targets Toxoplasmosis Through Modulating Host Toll-Like Receptor-MyD88 Signaling. <i>Frontiers in Immunology</i> , 2021, 12, 629917.	2.2	12
31	Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the dami cell line. <i>Biochemical Pharmacology</i> , 1997, 53, 1141-1147.	2.0	11
32	Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS. <i>Journal of Separation Science</i> , 2009, 32, 1363-1373.	1.3	11
33	Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action. <i>European Journal of Medicinal Chemistry</i> , 2021, 212, 113031.	2.6	11
34	Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 429-440.	1.4	10
35	Nitration in the imidazo[1,2-a]pyrazine series. Experimental and computational results. <i>Journal of Heterocyclic Chemistry</i> , 1997, 34, 701-707.	1.4	8
36	VASORELAXANT EFFECTS OF SCA40 (A PHOSPHODIESTERASE III INHIBITOR) IN PULMONARY VASCULAR PREPARATIONS IN RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1998, 25, 355-360.	0.9	7

#	ARTICLE	IF	CITATIONS
37	EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3421.	1.8	7
38	Fluorescence Study of Imidazoquinoxalines. <i>Journal of Fluorescence</i> , 2017, 27, 1607-1611.	1.3	5
39	Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503. <i>International Journal of Pharmaceutical Investigation</i> , 2017, 7, 155.	0.2	5
40	Effects of SCA40 on bovine trachealis muscle and on cyclic nucleotide phosphodiesterases. <i>European Journal of Pharmacology</i> , 1997, 334, 75-85.	1.7	4
41	Stearic acid pH-dependent reactivity in dipalmitoyl phosphatidylcholine model membranes in L <sup>1</sup> gel phase. An electron spin resonance and differential scanning calorimetry experiment. <i>Journal of the Chemical Society Faraday Transactions I</i> , 1989, 85, 3587.	1.0	3
42	Antiproliferative effects of imidazo[1,2- <i>b</i> ]pyrazine derivatives on the dami cell line. <i>Biochemical Pharmacology</i> , 1997, 54, 365-371.	2.0	3
43	Interaction and translocation of cysteamine (mercaptoethylamine) with model membranes: a 15N-NMR and 1H-NMR study. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 1997, 43, 73-81.	2.0	3
44	Apoptotic effects of imidazo[1,2- <i>a</i> ]pyrazine derivatives in the human Dami cell line. <i>European Journal of Pharmacology</i> , 1997, 320, 215-221.	1.7	3
45	Methylation of imidazopyrazine, imidazoquinoxaline, and pyrazoloquinoxaline through Suzuki-Miyaura cross coupling. <i>Chemistry of Heterocyclic Compounds</i> , 2018, 54, 183-187.	0.6	3
46	Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 369-379.	1.4	2
47	Modulation of the Megakaryoblastic Dami Cell Line Differentiation by Phosphodiesterase Inhibitors and Imidazo[1,2- <i>a</i> ]pyrazine Derivatives. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1997, 80, 286-289.	0.0	1
48	Substantial Cellular Penetration of Fluorescent Imidazoquinoxalines. <i>Journal of Fluorescence</i> , 2020, 30, 1499-1512.	1.3	1
49	Fused Azolo-Quinoxalines: Candidates for Medicinal Chemistry. A Review of their Biological Applications. <i>Current Medicinal Chemistry</i> , 2021, 28, 712-749.	1.2	1
50	Nutritional Supplements. , 2012, , 539-573.		0